Biological significance of promoter hypermethylation of p14/ARF gene: Relationships to p53 mutational status in Tunisian population with colorectal carcinoma by Ines Chaar et al.
RESEARCH ARTICLE
Biological significance of promoter hypermethylation
of p14/ARF gene: Relationships to p53 mutational status
in Tunisian population with colorectal carcinoma
Ines Chaar & Sameh Amara & Olfa Elhadj Elamine & Mariem Khiari &
Donia Ounissi & Taher Khalfallah & Abdelmajid Ben hmida &
Sabeh Mzabi & Saadia Bouraoui
Received: 14 May 2013 /Accepted: 11 September 2013 /Published online: 25 September 2013
# The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract One of the most important pathways which are fre-
quently affected in colorectal cancer is p53/ (MDM2)/p14ARF
pathway. We aim to determine the methylation pattern of p14/
ARF in relation to mutation of p53. This correlation was studied
to investigate whether their alterations could be considered as a
predictor factor of prognosis in colorectal cancer and whether it
can be useful in early-stage diagnosis. Statistical analyses show
that p14/ARF hypermethylation was correlated with rectum
location (p=0.004), primary TNM stage (p =0.016), and ad-
vanced Astler–Coller stage (p=0.024). The RT-PCR that revel
31% of patients did not express p14/ARFmRNA or at very low
level. A high concordance between CpG hypermethylation and
the low levels (p<0.005) was shown. In addition, our analyses
demonstrate that patients with mutation in the p53 gene have a
lack of the protein expression (p<0.005). This category with
negative expression of p53 had a shorter survival rate
(p <0.005). On the one hand, MSP pattern of p14/ARF were
correlated with a lack of p53 expression (p=0.007). We found
that p53/p14ARF pathway was frequently deregulated among
our patients. In our study, we demonstrate that hypermethylation
of p14/ARF occurs early during CRC tumorogenesis. However,
we did not find correlation between p14/ARF and survival.
These results suggest that p14/ARF methylation pattern may
constitute a predictor factor of CRC in early stage but it could
not be considered as a prognostic factor. On the other hand and
because of the reversibility of the methylation mechanism, it
may be appropriate to target the demethylation of p14/ARF to
develop new drogues for CRC.
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Introduction
Extensive molecular analyses have revealed that colorectal
carcinogenesis is characterized by a multistep process of ge-
netic and epigenetic alterations. P53/MDM2/p14ARF pathway
is usually affected in colorectal carcinogenesis. Indeed, these
proteins are actively involved in the apoptosis which represents
a principal physiological control mechanism. Any alteration
affecting one of these molecules could lead to abnormal cell
survival and will start the carcinogenesis process. The p53 is a
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key regulator of cell cycle checkpoints; it plays an important
role inducing cell death after DNA damage or under conditions
of cellular stress [1].
The prevalence of p53 mutations in colorectal cancer is
highly variable among different series and may be estimated
from 40 to 60% of patients [2, 3]. Its expression is maintained
at a very low level in the normal cells [4]. However, it has been
demonstrated that mutations in p53 gene increase the half life
of the protein which is associated with overexpression in the
nucleus [5]. Furthermore, the main cellular function of the
MDM2 oncoprotein is to control the level of p53 through an
autoregulatory feedback loop. In cancers, MDM2
overexpression deregulates this feedback, and the interaction
between MDM2 and p53 is blocked [6]. Recently, the p14/
ARF protein has been investigated acting as intermediate in
the MDM2/P53 pathway regulation.
This protein has been also identified as a tumor suppressor
gene promoting the rapid degradation of MDM2 and leading
to p53 stabilization and its nuclear accumulation [6, 7]. In fact,
p14/ARF bounds and blocks MDM2 to inhibit the
nucleocytoplasmic shuttling of p53 and induces its nuclear
retention, production, and activation [8–10]. Furthermore, it
acts upstream of p53 and answers to a negative feedback
regulation, which suggests that p53 mutations or its inactiva-
tion by MDM2 amplification are often accompanied by
overexpression of p14/ARF [11]. P53-positive tumors are also
likely to have sustained epistatic mutations such as MDM2
amplification or p14/ARF loss or inactivation [12]. Nuclear
import and export is a feature of both p53 and MDM2, such
that nuclear p53 absence is associated with tumors with a poor
prognosis [13]. Many analyzes suggest that p14/ARF influ-
ences the subcellular localization of MDM2 [14]. Conse-
quently, the localization of these proteins and the relationship
between their levels of expression are likely to be important in
many carcinogenesis. Previous studies have examined p14/
ARF mRNA expression in breast cancers, with evidence
suggesting altered expression and an association with p53
[15, 16].
Moreover, the literature describes other process by which
p14/ARF gene can be inactivated in many cancers such as
deletion, promoter hypermethylation, or mutations [17]. In
colorectal cancer (CRC), the p14/ARF inactivation was proved
to be the result of promoter hypermethylation [18]. This last
seems to be rich in CpG dinucleotides methylation of the
cytosine residues at the CpG islands; this region plays an
important role in the inactivation of gene expression. The
transcription of p14/ARF can be deregulated by the hyperme-
thylation [18]. Transcriptional silencing of the p14/ARF gene
through CpG hypermethylation of the DNA promoter is an
important event in the genetic regulation of cancers and would
be associated with its carcinogenesis process [18]. This epige-
netic mechanism occurs in many cancers and was mainly
studied in glioma and bladder cancers [17, 19]. Actually, only
few recent studies were published concerning hypermethylation
and loss of expression of p14/ARF in colorectal cancer [7, 20].
The complexity and the close relationship between p53 and
p14/ARF prompted us to describe these mutational profiles
and expression in Tunisian colorectal cancer. In our study, we
aimed to determine the p14/ARF expression level and its
promoter methylation pattern in relation to mutational status
of p53. First, we analyzed the relationship between epigenetic
profiles and mutation status of p14/ARF and p53 genes with
clinicopathological parameters. Next, we investigatedwhether
the promoter methylation and the mRNA expression, respec-
tively of p14/ARF and p53, were a predictor of the disease
progression and the prognosis of colorectal cancer patients in
Tunisian population.
Patient specimens
We underwent a retrospective study from 1995 to 2011 regard-
ing patients with CRC, diagnosed in the laboratory of Pathology,
Mongi Slim Hospital, Tunis. The individuals had neither gas-
trointestinal diseases nor a history of tumor. In the 167 cases
included in this study, samples were taken not only from the
tumoral area but also from the margin, corresponding to distant
resection and were histologically free from precancerous lesions
and cancer. The data collected for all patients included sex, age,
tumor localization, TNM stage, and Astler–Coller stage. For
DNA and the RNA extraction, representative samples of frozen
sample tumoral mucosa (112) and paraffin-embedded tissues
(55) were obtained from the files of 167 patients with CRC. The
patient group included 83 women and 84 men. The mean age of
the Tunisian patients (at the time of tissue collection) was
57 years. On histological exam, the tumor location was divided
into 99 colon and 68 rectum. Furthermore, the pathologic clas-
sification of tumors was made according to the international
TNM staging system: we identified 30 in primary stage (stages I
and II) and 137 in advanced stage (stages III and IV).
Concerning the Astler–Coller stage, we found 53 cases at early
Astler–Coller stage and 114 at the advanced ones.
Methods
DNA and RNA extraction
Twenty milligrams of genomic DNA was extracted from par-
affin embedded and frozen samples of tumoral mucosa. They
were treated using the Wizard SV Genomic DNA Purification
System according to the manufacturer’s instructions (Promega,
Madison, WI). The concentration of the DNA was measured
with a spectrophotometer. Total RNA was extracted with
TRIZOL reagent (Invitrogen) according to the manufacturer’s
instructions. After purification, RNAwas dissolved in DEPC-
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treated water. The cDNAwas synthesized by M-MLV Reverse
Transcriptase (Invitrogen) and stored at −20 °C until used.
Sodium bisulfite modification of DNA(cDNA synthesis)
and methylation-specific PCR of p14/ARF
Two micrograms of genomic DNA from each sample were
bisulfite-modified using the EZ DNA methylation kit (ZYMO
Research, Orange, CA) according to the manufacturer’s in-
structions. After treatment, the resulting bisulfite-modified
DNAwas eluted in 10 μL of the kit elution buffer and stored
at −20 °C. Two microliters of the bisulfite-modified DNAwere
used for each PCR reaction. Two microliters of bisulfite-
modified DNA from each sample were amplified independent-
ly using the U- andM-specific primers in a 25-μL total volume
reaction (Table 1). Each PCR reaction contained a final con-
centration of 0.4 mmol of each primer (SGS, Köping, Sweden),
0.5-mmol dNTPs, 1× PCR buffer (Promega), 1.5-mM MgCl2
(Promega), and 0.04 units of Taq polymerase (Promega). The
PCR products were checked on-chip electrophoresis.
RT-PCR for detection of p53 and p 14/ARF mRNA
expression
Total RNA was reverse-transcribed by M-MLV reverse tran-
scriptase (Invitrogen) from which the c DNA was obtained
from PCR reaction. PCR primers for p53 and β-actin were
outlet in Table 1. RT-PCR of p53 was conducted with an initial
step for 5 min at 95 °C followed by 40 cycles of 15 s at 95 °C
and 1 min at Tm (degrees Celsius). cDNA integrity was con-
firmed by β-actin-specific PCR analyzes. The RT-PCR-
products were checked on chips electrophoresis. The amplified
band was 379 bp for p53, 207 bp for p14/ARF, and 581 bp for
β-actin.
Analyzes of p14/ARF and p53 amplification product
by on-chip electrophoresis
The PCR products of p14/ARF and p53 migration have been
performed by chips-electrophoresis, for that, we used DNA
1000 LabChips kits, prepared with gel-dye mix, pressurized,
Table 1 Detail of the primers and




SpUF : TTTTTGGTGTTAAAGGGTGGTGTAGT 122 58°
SpUR: CACAAAAACCCTCACTCACAACAA
M






SPF: CCAGGCACCAGGGCGTGATGGTGGGCATGG 581 56°
SPR: AGCAGCCGTGGCCATCTCTTGCTCGAAGTC
P14/ARF




Sp5F: TGTTCACTTGTGCCCTGACT 266 54°
Sp5R: CAGCCCTGTCGTCTCTCCAG
Exon 6
Sp6F: GCCTCTGATTCCTCACTGAT 160 53°
Sp6R: TTAACCCCTCCTCCCAGAGA
Exon 7
Sp7F: ACTGGCCTCATCTTGGGCCT 180 56°
Sp7R: TGTGCAGGGTGGCAAGTGGC
Exon 8
Sp8F: TAAATGGGACAGGTAGGACC 230 54°
Sp8R: TCCACCGCTTCTTGTCCTGC
Tumor Biol. (2014) 35:1439–1449 1441
then a marker solution and DNA 1500 ladder were added. For
this process, 1 μL of each PCR reaction was added into one
out of 11 sample wells of a prepared chip. After vortexing, the
chip was placed in the BioRad Experion bioanalyzer. The
electrophoresis of samples lasted approximately 30 or
40 min. Fragment analyzes was conducted using BioRad
Experion software, and an overlay of two electropherogram
was used to compare PCR patterns derived from tumor and
normal mucosa. Differences in the peak patterns of the over-
laid electropherogram were evaluated and two were used for
each patient.
Mutational analyzes of p53: PCR amplification and SSCP
analyzes
Exons 5 to 8 of p53 gene were amplified by polymerase chain
reaction (PCR). The amplification products of p53 were re-
solved on on-chip electrophoresis. Primer sequences outlet in
Table 1. An independent PCR assays was performed for each
exon. The standard PCR reaction contained 0.5 μg genomic
DNA, 200 μmol/L dNTPs, 1× PCR buffer (Promega),
1.5 mmol/L MgCl2, 1 U of Taq DNA polymerase (Promega),
0.3 μmol/L of each primer (biomatik), H2O, and 5 % dimethyl
sulfoxide.
A 2-μL volume of p53 PCR product was denatured in 5 μL
of formamide, incubated for 10 min at 95 °C. The overall
mutation rate of p53 was identified after chips electrophoresis
by the presence of one or two extra bands migration above or
below the normal single-stranded products. Occasionally, mu-
tated bands were detected between the single and double-
strand bands that may be caused by formation of normal-
mutated heterodimers. Samples with mobility shift were con-
firmed by sequencing using Sanger methods.
Immunohistochemistry of p53 protein
Serial sections of 4-mm thickness were cut from formalin-
fixed paraffin-embedded samples, incubated in an oven at
37 °C overnight, deparaffinized, and rehydrated. The slides
were immersed in citrate buffer (pH=6.0) in a microwave for
2–5 min to unmask the epitopes and then kept at room
temperature for 20 min, followed by a Tris-wash for 5 min.
The sections on the slides were incubated with peroxidase
block to inhibit endogenous peroxidase activity. After wash-
ing twice in Tris, the sections were incubated in p53 (1:50,
Vision Biosystems) at room temperature for 1 h. They were
then incubated with postprimary block for 30 min. Expres-
sions were assessed after incubation of the sections at room
temperature with the peroxidase-labeled DAKO Envision
System for 30 min, using DAB as a chromogene for 20 min.
After washing with distilled water, the sections were then
counterstained with hematoxylin. The reaction was consid-
ered as positive when a positive nucleus staining of p53.
Statistical analyzes
The relationships between p14/ARF, p53 gene status and the
different clinicopathological variables were assessed using χ2
test. The odds ratio was obtained by unconditional logistic
regression analyzes. Survival curves were computed according
to the Kaplan–Meier method. All p values cited were two-
sided and p values of <0.05 were judged as statistically signif-
icant. SPSS software, version 17.0, was used for analyzes,
Results
Analyzes of methylation status and mRNA expression
of p14/ARF: correlation with clinicopathological data
Of 167 patients with CRC, 120 (71.8 %) cases were
unmethylated (U), 33 (19.7 %) methylated (M), and 14
(8.5 %) methylated and unmethylated (MU) at the same time
(Fig. 1). Statistical analyzes shows that the MSP pattern was
correlated with location (p =0.04), Astler–Coller stage
(p =0.024) and with TNM stage (p=0.016). In fact, we found
that 65 % of U phenotype was seen in the colon compared with
M and MU phenotype distribution which was equivalent be-
tween colon and rectum. For the prognosis factor, the MSP
pattern demonstrates that the M and MU bands were correlated
with the primary TNM stage: Stages I and II (Table 2) and with
advanced Astler–Coller stage (stages C and D; p=0.024). How-
ever, we do not find any statistical association between p14/ARF
MSP pattern and the other clinicopathological criteria.
We also examined the expression of p14/ARF using RT-
PCR. Among 167 early lesions with available cDNA, 101/120
colorectal adenomas which are U at p14/ARF expressed high
levels of p14/ARF mRNA, whereas 23/52 adenomas with
p14/ARF M and 10/52 with MU pattern do not expresses
p14/ARF mRNA or very little p14/ARF mRNA level, dem-
onstrating an exact correlation of transcriptional loss with p14/
ARF hypermethylation (p <0.005; Fig. 2; Table 3). No corre-
lation was found with clinicopathological features.
Analyzes of mRNA expression, mutational status
and immunostaning of p53 in CRC: correlation
with clinincopathological data
The samples were considered negative when they were posi-
tive for β-actin and negative for p53 (Fig. 2). In our set, 109
cases (65.3 %) showed positive expression for p53 while 58
(34.7 %) cases were negative (Table 3).
The p53 exons 5, 6, 7 and 8 were successfully amplified in all
cases, which gave expected PCR fragment of 266, 160, 180, and
230 bp, respectively. After SSCP analyzes, among 167 cases of
CRC, 17.4 % (29/167) was found harboring altered p53. Fur-
thermore, 11 cases showed alterations in exon 5, 5 in exon 6, and
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14 in exon 7, whereas no mutation was found in exon 8 (Fig. 3).
Out of these 29 cases, 19 (65.5 %) were transition and 10
(34.5 %) transversion. All mutated samples in SSCP analyses
were confirmed by sequencing (Fig. 3a, b; Table 4). No signif-
icant involvement has been detected through our statistical anal-
yses between p53, SSCP analysis, or p53mRNA expression and
clinicopathological variables. The comparison between p53
mRNA expression and p53 alteration revealed an association
among the variables (p<0.005). In fact, we found that 75.9 %
(22) of patients who had mutation in the p53 gene have a lack of
the protein expression (Table 5).
For the immunoreactions, there were no significant differ-
ences with respect to clinicopathological characteristics be-
tween weak, moderate, or strong staining. Therefore, the three
latter groups were classified as positive in our following ana-
lyzes. In total, 57 (34.1 %) of the 167 tumors showed positive
immunoreactivity for p53. The immunoreactivity of p53 was
invariably confined to the nucleus, and normal mucosa samples
were negative for p53 expression (Fig. 4a) and positive in the
tumoral area (Fig. 4b). According to clinicopathological vari-
ables, no significant involvement was detected through our
statistical analyses except for the TNM stage. However, p53
was associated with TNM advanced stage, and we found a loss
of expression of p53 (86.4 %) in stages III and IV (p =0.037;
Table 2).We found significant association between p53 expres-
sion andmutational status analyses (p <0.005; Table 6). Indeed,
we observed that the patients with negative expression of p53
demonstrate the absence of mobility shift in the DNA by SSCP
Fig. 1 MSP analysis of p14/ARF for different patients with colorectal
cancer;U andM indicates the U and theM fragments, respectively. Lanes
L , ladder at 1,500 bp; NC, negative control of PCR (without primers); 1 ,
positive controls of U reaction; 2 , positive controls of M reaction. For
patient 1, lanes 3 and 4 reveal the presence of U band and the absence of
M band, respectively. For patient 2, lanes 5 and 6 reveal the presence of
the U and M band respectively in the same tumor. Patient 3 reveals the
absence of U band and the presence of M band (M) in lanes 7 and 8 ,
respectively. Inset , comparison report of density of UM and MU pattern
of p14/ARF
Table 2 Number of CRC samples with p14/AFRmethylation pattern, p53 mRNA expression, p53 mutation status, and P53 immunostaning analysis in
relation to clinicopathological parameters n (percent)
Variables P14/ARF MSP pattern P53 mutation status P53 mRNA expression P53 immunostaning
U M U+M p + − p + − p + − p
120 (%) 33 (%) 14 (%) 29 (%) 138 (%) 58 (%) 109 (%) 57 (%) 110 (%)
Sexe
Male 63 (52.5) 17 (51.5) 4 (28.6) 0.11 12 (41.4) 72 (52.1) 0.19 33 (56.9) 51 (46.8) 0.14 31 (54.4) 70 (63.7) 0.21
Female 57 (47.5) 16 (48.5) 10 (71.4) 17 (58.6) 66 (47.9) 25 (43.1) 58 (53.2) 24 (45.6) 41 (36.3)
Age (year)
<65 78 (65) 15 (45.5) 8 (57.1) 0.21 17 (58.6) 84 (60.1) 0.49 31 (53.4) 70 (64.2) 0.11 33 (57.9) 51 (46.4) 0.11
≥65 42 (35) 18 (54.5) 6 (42.9) 12 (41.4) 54 (39.9) 27 (46.6) 39 (35.8) 24 (42.1) 57 (53.4)
Site
Colon 78 (65) 16 (48.5) 5 (35.7) 0.040 18 (62) 81 (58.7) 0.45 40 (69) 59 (54.1) 0.044 37 (64.9) 56 (50.9) 0.11
Rectum 42 (45) 17 (51.5) 9 (64.3) 11 (38) 57 (41.3) 18 (31) 50 (45.9) 20 (35.1) 54 (49.1)
TNM stage
Stage I+II 23 (19.2) 7 (21.2) 0 (0) 0.016 4 (13.8) 26 (18.7) 0.38 11 (19) 19 (17.4) 0.48 15 (26.3) 15 (13.6) 0.037
Stage III+IV 97 (80.8) 26 (78.7) 14 (100) 25 (86.2) 112 (81.3) 47 (81) 90 (82.6) 63 (73.7) 74 (86.4)
Astler–Coller stage
Stage A+B 45 (37.5) 7 (21.2) 1 (7.1) 0.24 21 (72.4) 94 (68.1) 0.41 44 (75.8) 71 (65.1) 0.1 49 (86) 87 (79) 0.18
Stage C+D 75 (62.5) 26 (68.8) 13 (92.9) 8 (27.6) 44 (31.9) 14 (24.2) 38 (34.9) 8 (14) 23 (21)
Fig. 2 Chips electrophoresis of p53 and p14/ARF mRNA expression in
colorectal cancer tissues. Lanes L , ladder at 1,500 bp; NM , mRNA
expression of p53 and p14/ARF in normal mucosa normalized with B-
actin; 1–6 reveal the presence of β-actin in all cases; 1 , 3 , 4 , and 6
showed expression of p53 in 372 bp, and therefore, 2 and 5 revealed lack
of p53 mRNA expression in 372 bp position; 1 , 2 , 3 , 5 showed expres-
sion of p14/ARF, and therefore, 4 and 6 revealed lack of p/14ARF
mRNA expression in the 207-bp position
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analysis at 28.26 % (39/138), and the patient with
overexpression of p53 demonstrate the presence of mobility
shift in the DNA by SSCP 3at 1.1 % (9/29).
Relationship between the p14/ARF methylation and p53
analyzes
Statistical results did not show any association between the
methylation pattern of p14/ARF and the mutational status of
p53. Interestingly, combined analyses of p53 mRNA expres-
sion and p14/ARF methylation pattern showed a significant
association. In fact, we found that the majority of cases withM
(26 cases) and UM (13 cases) patterns of p14/ARF were
correlated with a lack expression of p53 (p =0.007; Table 3).
The relationship between the alteration in p14/ARF and p53
and patients survival
The Kaplan–Meier survival curve for p14/ARF showed that
there was no correlation between its methylation pattern and
the specific disease survival (p =0.41; Fig. 5a). For the p53
mRNA expression, we found that the patients with negative
expression of p53 had shorter survival than patients with
positive expression of p53 (p =0.000; Fig. 5b).
Discussion
The p14/ARF is considered as a tumor suppressor protein, its
inactivation by hypermethylation has been extensively de-
scribed in many cancers [4, 11]. The frequency of its promoter
hypermethylation varies in different tumor types [21]. This
last alteration was particularly intriguing in view to the inter-
play between p14/ARF and its impact in the p53 pathway
during tumorogenesis.
Table 3 Relationship among p14/ARF methylation, p53 mRNA expres-
sion, and SSCP analysis in colorectal cancer patients
P14/ARF
U (%) M (%) U+M (%) p
n =120 n =33 n =14
P14/ARF
RT+(n =115) 101 (84.2) 10 (30.3) 4 (28.6) <0.005
RT−(n =52) 19 (15.8) 23 (69.7) 10 (71.4)
p53
RT+(n =58) 50 (41.7) 7 (21.2) 1 (7.1) 0.007
RT−(n =109) 70 (58.3) 26 (78.8) 13 (92.2)
P53 mutation status
M (n =29) 21 (17.5) 7 (21.2) 1 (7.1) 0.5
WT (n =138) 99 (82.5) 26 (78.8) 13 (92.9)
M mutation, WT wild type
Fig. 3 a Single-strand
conformational polymorphism
analysis of exons 5, 6, 7, and 8 of
the p53 gene. Lanes L , ladder at
1,500 bp; 1 , exon 5 tumoral
sample with 266-bp band; 2 , exon
5 WT; 3 , exon 5 sample with
mutated band; 4 , tumoral sample
of exon 6 with 160-bp band; 5 ,
exon 6 sample withWild Type; 6 ,
exon 6 sample with mutated band;
7 , tumoral sample of exon 7 with
180-bp band; 8 , exon 7 sample
with wild type; 9 , exon 7 sample
with mutated band; 10, tumoral
sample of exon 8 with 230-bp
band; and 11 , exon 8 sample with
wild type. M mutated, WT wild
type. b Partial electropherograms
representing the normal and
mutant profiles of exons 5, 6, and
7. A , Insertion of T. B , Insertion
of C. C , transition of G to A
leading to a frame-shift mutation
1444 Tumor Biol. (2014) 35:1439–1449
Methylation status of p14/ARF in colorectal cancer re-
mains unclear and is until now not studied in Tunisian popu-
lation. Therefore, to elucidate the implication of p14/ARF
through the colorectal carcinogenesis, the MSP pattern,
mRNA expression, and different clinicopathological data
were studied.
In this study, the methylation of the p14/ARF gene oc-
curred in 28.2 %. This level among colorectal cancer patients
varies between 22 and 50%. This difference may be due to the
diversity of populations [22–24].
TheMSP pattern of p14/ARF are habitually represented by
two entities: U and M patterns. Interestingly, in a recent paper,
we have published [18], a new result was found showing the
presence of U and M bands in the same sample that indicates
the hemi-methylated pattern (MU) [18]. This proportion rep-
resents 8.5 % of our set. These bands were analyzed in terms
of intensity, and we found that the majority of cases showed a
greater intensity of the methylation band. This result confirms
that it is a physiological and progressive transition from the U
pattern towards the promoter hypermethylation. Comparing
p14/ARF MSP pattern with clinicopathological parameters
showed an association between p14/ARF hemi-methylated
pattern and CRC rectum site (p =0.04). Indeed, our analysis
revealed a similar distribution of p14/ARF methylation
Table 4 Sequencing of P53 in 29
patients with colorectal cancer Exon/codon WT codon Mutant codon WTAA Mutant AA Effect ID Cancer
E5/181 CGC TGC Transition ARG CYS MS 17 CRC
E5/175 CGC CAC Transition ARG HIS MS 20 CRC
E5/173 GTG ATG Transition VAL MET MS 37 CRC
E5/154 GGC GGT Transition ARG TRP MS 39 CRC
E5/166 TCA ATC Transversion SER ILE FM 64 CRC
E5/177 CCC CTC Transition PRO LEU MS 112 CRC
E5/159 GCC GAC Transition ALA ASP MS 113 CRC
E5/176 TGC TGG transition CYS TRP MS 128 CRC
E5/126 CAG TAG Transition GLU STOP TP 132 CRC
E5/171 GAG CAG Transversion GLU GLN MS 147 CRC
E5/175 CGC CAC Transition ARG HIS MS 148 CRC
E6/196 CGA TGA Transition ARG STOP TP 74 CRC
E6/205 TAT CAT Transition TYR HIS MS 22 CRC
E6/204 CAG TAG Transition LYS STOP TP 68 CRC
E6/213 CGA CTA Transversion ARG LEU MS 121 CRC
E6/209 AGA AAA Transition AGR LYS MS 6 CRC
E7 /229 TGT TGA Transversion CYS STOP TP 2 CRC
E7/248 CGG TGG Transition ARG TRP MS 19 CRC
E7/245 GGC AGC Transversion GLY SER MS 28 CRC
E7/234 TAC CAC Transition TYR HIS MS 72 CRC
E7/248 CGG CAG Transition ARG GLN MS 58 CRC
E7/250 CCC CTC Transition PRO LEU MS 162 CRC
E7/254 ATC ACC Transition ILE THE MS 10 CRC
E7/238 TGT TAT Transition CYS TYR MS 11 CRC
E7/242 GAG TAG Transversion GLU STOP TP 82 CRC
E7/239 GGC AGC Transversion GLY SER FM 83 CRC
E7/244 GGC AGC Transversion GLY SER FM 15 CRC
E7/283 TGT TGA Transversion CYS STOP TP 67 CRC
E7/248 CGG CCG Transversion ARG PRO MS 122 CRC
E7/248 CGG CAG Transition ARG GLN MS 92 CRC
Table 5 Relationship among p53 m RNA expression and p53 mutation
in colorectal cancer patients n (percent)
P53 mRNA expression p
Negative expression Positive expression
p53 mutation status
SSCP+M 22 (75.9) 7 (24.1) <0.005
SSCP–WT 36 (26.1) 102 (73.9)
SSCP+ positive mobility shift of p53 (p53 mutated profile), SSCP−
negative mobility shift of p53 (p53 wild type)
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between the colon (48.5 %) and the rectum (51.5 %). More-
over, hemi-methylated pattern was generally observed in the
rectum (64.3 %). However, Burri et al. demonstrate that
methylation of p14/ARF gene was significantly more frequent
in right-sided than in left-sided tumors [25]. In this frame, Lee
et al. showed no statistical significance between the MSP
pattern and colorectal cancer site [23].
Based on the prognostic parameters, we did not detect any
association between the hypermethylation and the survival
rate. This result was similar to many previous studies of the
literature [21, 26].
Conversely, we found that methylation of p14/ARF pro-
moter gene was associated with the stage of the disease. In
fact, in the primary TNM stages of our tumors, stages I and II,
the M and hemi-methylated status were seen at 57.6 and
100 %, respectively (p =0.016). Furthermore, the infiltrative
growth of the tumor (p =0.024; Astler–Coller C and D) was
associated with M and hemi-methylated pattern of the pro-
moter gene. These results showed that the inactivation of p14/
ARF were associated with early stages of the tumor which
were also characterized by small diameter and absence or rare
metastatic lymph nodes. Despite their primary stages, these
tumors were correlated with infiltrative growth process. These
results proved that these patterns are very aggressive.
Dominguez et al. [27] also reported a significant correlation
between methylation of p14/ARF gene and poor prognosis in
breast, colon, and bladder carcinomas. Thus, our result and
those of the literature indicate that methylation process con-
stitutes the major mechanism of p14/ARF inactivation and
could be used as a biomarker for CRC [18].
P14/ARF is a candidate for hypermethylation with loss and
inactivation of its protein. It contains a documented CpG
island which can be silenced by this genetic and epigenetic
alteration. However, few works have evaluated the methyla-
tion of p14/ARF in association with its expression. For further
comprehension of this loss, we associate this fact to its regu-
lation by mRNA expression. Therefore, we conducted a spe-
cific analysis of p14/ARF mRNA expression by RT-PCR and
evaluated its impact in the genesis and prognosis in our cohort.
Interestingly and according to our results, a high concordance
was shown between CpG hypermethylation and the low levels
of the p14/ARF mRNA pattern (p <0.005). Consequently, our
data confirmed by others in recent literature, suggests that
epigenetic regulation by promoter hypermethylation is the
predominant mechanism involved in the deregulation of
p14/ARF and may contribute to silencing of p14/ARF mRNA
expression in CRC patients [28–30].Moreover, no association
was found between p14/ARF mRNA expression and patient
survival.
According to these results, we can conclude that the inac-
tivation of tumor suppressor genes by aberrant hypermethyla-
tion is a fundamental process involved in the progression of
many malignant tumors, including gastrointestinal cancer [31,
32].
After rigorous validation on RT-PCR and immunohisto-
chemistry investigation, a molecular signature associated with
p53 mutant phenotypes in this subset of CRC was identified.
Approximately the same values were found between the p53
transcriptional (mRNA) and translational (protein) profile
with the p53 mutation status. In fact, we note that mutant
forms of p53 have two distinct expressions phenotypes name-
ly positive or negative. This could be the result of different
mutations in the p53 gene: activation or inactivation mutation.
With regard to the p53 wild type, the lack of expression (39
and 36 cases) is probably associated with the involvement of
epi-mutation (p53 promoter hypermethylation), knowing that
these data have been recently reported in the literature.
Therefore, we found that p53 mutation and its abnormal
expression may affect the occurrence and the development of
CRC in synergy. It was reported that in 50 % of human
Fig. 4 p53 Nuclear
immunostaning. a Negative
expression of p53 in healthy
mucosa. b Positive expression of
p53 in colorectal cancer. Inset ,
high magnification of p53
expression in tumor
Table 6 Relationship between p53 protein expression detected by IHC
and p53 gene mutation status of 167 CRC patients n (percent)
P53 IHC−10 % IHC+10 % p
M 20 (68.9) 9 (31.1) <0.005
WT 39 (28.26) 99 (71.74)
M mutated, WT wild type
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cancers, the p53 gene is mutated. The gain of oncogenicity or
the loss of tumor suppressor function of p53 is due to two
alterations, such as its inactivation through missens mutations
or its overexpression by transcription of p53 mutant form.
This fact is considered as metastatic signatures in CRC [33].
It contributes to tumor aggressiveness and results in poor
survival [34–37].
The present study demonstrates an association between
p53-negative mRNA expression and poor survival in our
cohort. The genomic instability associated with p53 mRNA
overexpression is the cause of developing a risk phenotype,
aggressive progression, and early death as reported in previ-
ous works [32, 38].
The basic functions of p14/ARF inactivation, is predicted
to reduce the p53 aberrant protein resulting from the mutation
of the p53 [32]. Many researches showed that high frequency
of p14/ARF promoter methylation had been previously re-
ported to occur in tumors without TP53 mutations [4, 38]. An
inverse correlation between TP53 mutations and epigenetic
inactivation of p14/ARF in CRC do not always hold true [39].
Conversely, p53/p14/ARF axis was considered as the ma-
jor pathway involved in the regulation of cell proliferation,
apoptosis, and DNA repair [40, 41]. Although these two
proteins are mechanically dependant, this complex was (p53/
p14/ARF) frequently deregulated through the strong associa-
tion between p53 expression and p14/ARF methylation. In
fact, we showed that M (78.8 %) and hemi-methylated
(92.2 %) patterns were observed in tumor samples with a lack
of p53 expression. This result is logical as p14/ARF methyl-
ation causes loss of p14/ARF functions and induces its ab-
sence in the nucleolus. As a result, it cannot bind to MDM2,
resulting in its liberation. In this case, MDM2 acts as an
oncogene, degrade p53 by ubiquitinylation, and blocks the
normal cell cycle.
In the literature, controversial results between p53 expres-
sion and p14/ARF inactivation has been observed not only in
CRC but also in gastric and lung carcinomas [5, 42–45].
Eischen et al. [46] reported that control of p53 by p14/ARF
occurs under specific stressful conditions and their effects on
p53 functions may be dependent of the p53/p14ARF pathway
in some tumor types. If one gene is abnormal, the p53/p14/
ARF pathway function is blocked.
In conclusion, we found that p53/p14/ARF pathway was
frequently deregulated in our patients. Herein, we demonstrate
that hypermethylation of p14/ARF occurs early during CRC
tumorogenesis. However, we did not find any correlations
between p14/ARF and survival. These results suggest that
p14/ARFmethylation pattern may constitute a predictor factor
of CRC in early stage but it cannot be considered as a prog-
nostic factor.
Finally, simultaneous assessment of p14/ARF methylation
and abnormal expression of p53 may work as a biological
indicator for early diagnosis of colorectal cancer, which may
provide a theoretical basis for genetic intervention in clinical
practice. With regard to our results, several revolutionary
prospects can be opened in modern oncology: (1) Intervention
of p14ARF methylation may be considered a powerful bio-
markers in early colorectal cancer diagnosis. (2) Knowing that
the methylation process is a reversible phenomenon, demeth-
ylation could be considered as targeted therapy.
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